Current and Emerging Data on SGLT2 Inhibitors in Heart Failure

Published: 03 December 2019

  • Views:

    Views Icon 188
  • Likes:

    Heart Icon 2

Overview

Full programme

  • Views:

    Views Icon 188
  • Likes:

    Heart Icon 2

Overview

The opportunity for cardiovascular disease prevention in patients with type 2 diabetes mellitus (T2DM) has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE) including sodium-glucose co-transporter-2 (SGLT2) demonstrating robust reductions in heart failure (HF). Although the exact mechanisms of cardiovascular (CV) benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects.

Recent trials — including the recently presented DAPA-HF — have provided further insight into the effectiveness of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in the absence of T2DM.
 

EBAC Accreditation

This video is funded by an unrestricted educational grant from AstraZeneca.

Learning Objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data; differentiate the latest guideline updates for the treatment of T2D
  • Consider comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF)
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF
  • Assess the interrelationships linking diabetes, HF and CVD
  • Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
  • Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.

Series overview

Part 1

SGLT2 in HF Now and the Future

1 session

Part 2

DAPA-HF Trial Design Rationale

1 session

Part 3

SGLT2 beyond diabetes

1 session

Part 4

Guidelines, Recent Data & Future Practices

1 session

  • Guidelines, Recent Data & Future Practices

    Watch now

Part 5

DAPA-HF Trial

1 session

Part 6

Discussion with the DAPA-HF Trialist

1 session

  • Discussion with the DAPA-HF Trialist

    Watch now

Faculty biographies